Gene · 7332
UBE2L3: ubiquitin conjugating enzyme E2 L3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. UBE2L3: ubiquitin conjugating enzyme E2 L3. Genes, record 7332. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/7332
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P68036 | Ubiquitin-conjugating enzyme E2 L3 | 154 | 21 | Ensembl, GeneID, HGNC |
Source UniProt
Patents37
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 69077 | P68036 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 6880 | P68036 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 6880 | P68036 | Espacenet |
| EP 4463571 A1 | 2024-11-20 | 265 | P68036 | Espacenet |
| JP 2023550743 A | 2023-12-05 | 85 | P68036 | Espacenet |
| JP 2023504790 A | 2023-02-07 | 15 | P68036 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 95243 | P68036 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 198214 | P68036 | Espacenet |
| JP 2021525807 A | 2021-09-27 | 11 | P68036 | Espacenet |
| EP 3805256 A1 | 2021-04-14 | 11 | P68036 | Espacenet |
1 to 10 of 37
See all 37 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,230
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | UBE2L3 papers | Newest fiscal year |
|---|---|---|---|
| P30CA021765 | Cancer Center Support Grant (CCSG) | 16 | 2025 |
| R01AI024717 | Genetic Linkage in Lupus | 8 | 2025 |
| R01AR063759 | Defining the influence of RA genetic susceptibility factors on T cell antigen specificity and functional state | 7 | 2025 |
| U54GM104938 | Oklahoma Shared Clinical and Translational Resources | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 5 | 2025 |
| ZIABC010440 | Protein Structure, Stability, and Amyloid Formation | 5 | 2025 |
| ZIABC010441 | Biomolecular Recognition and Binding Mechanisms | 5 | 2025 |
| P30CA014195 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
| U01DK062423 | Genomic and Immunologic Characterization of Inflammatory Bowel Disease and its Phenotypes | 4 | 2025 |
1 to 10 of 1,230Source NIH's project files
See all 1,230 nih grantsPapers1,458
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Fluorophore placement and size impact E2 ubiquitination efficiency. | Biochem J | 2026 | 42770861 | PubTator, text mining | PubMed |
| Integrative analysis of gastric tissue transcriptomes and gastric cancer GWAS implicates candidate susceptibility genes. | Am J Hum Genet | 2026 | 42392035 | PubTator, text mining | PubMed |
| In vivo CRISPR/Cas9 Screening Reveals that UBE2L3 Modulates Autophagic Flux through TSC2 Ubiquitination and Potentiates PD-1 Blockade in Triple-Negative Breast Cancer. | Int J Biol Sci | 2026 | 41943836 | PubTator, text mining | PubMed |
| Meta-Analysis of Genetic Variants Associated With HBV Infection Susceptibility and Hepatocellular Carcinoma Risk. | J Viral Hepat | 2026 | 41937404 | PubTator, text mining | PubMed |
| Transcriptome sequencing (RNA-Seq) reveals non-coding pseudogene CDC27P9 role in cervical cancer. | Apoptosis | 2026 | 41874705 | PubTator, text mining | PubMed |
| TRIM proteins as emerging regulators of immune pathways: potential therapeutic targets in immune-related disorders. | Front Immunol | 2026 | 41756277 | PubTator, text mining | PubMed |
| "Lys-Leu" Motif Empowers Expedient OaAEP1-Catalyzed Generation of N‑Terminal Cysteine Recombinant Proteins for Bioconjugation and Semisynthesis. | JACS Au | 2026 | 41755832 | PubTator, text mining | PubMed |
| SMURF1 Downregulation Highlights Its Potential Role in Breast Cancer. | Int J Mol Sci | 2026 | 41752056 | PubTator, text mining | PubMed |
| Structure-guided analysis and prediction of human E2-E3 ligase pairing specificity. | bioRxiv | 2026 | 41726935 | PubTator, text mining | PubMed |
| The E3 ubiquitin ligase mechanism specifying target-directed microRNA degradation. | bioRxiv | 2026 | 41542392 | PubTator, text mining | PubMed |
1 to 10 of 1,458
See all 1,458 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/7332
GET https://conductscience.org/api/genes/v1/7332/patents?page=2